Treatments targeting MDS genetics: A fool's errand?

Research output: Contribution to journalArticle

Abstract

The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

Original languageEnglish (US)
Pages (from-to)277-285
Number of pages9
JournalHematology (United States)
Volume2018
Issue number1
DOIs
StatePublished - Nov 30 2018

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatments targeting MDS genetics: A fool's errand?'. Together they form a unique fingerprint.

  • Cite this